Losing weight is something that millions of people struggle with, and for many, the solution may lie in medical or surgical ...

While older anti-obesity drugs may lead to less weight loss than semaglutide and tirzepatide, they remain useful tools in ...

Wegovy is a GLP-1 agonist containing semaglutide, the same active ingredient as Ozempic. While both medications share this ...

University of Utah Health offers comprehensive weight management options for patients looking to achieve and maintain a ...

With so many medical options available, deciding which path to take can be overwhelming. Whatever route you choose, remember that there is no magic bullet for sustainable weight loss. Long-term ...

There are many ways to lose weight, but finding the best path can be difficult without assistance. The doctors at Ascension ...

A Cleveland Clinic study reveals that bariatric surgery significantly reduces the risk of serious liver complications in ...

In this video, Jamy D. Ard, MD, FTOS, discusses treatment options, lifestyle interventions and strategies for patients with ...

Nearly 70% of adults in Indiana are classified as overweight or obese, contributing to a broader health crisis in the United States.

In the first half of 2025, Ozempic developer Novo Nordisk in Bagsværd, Denmark, expects results from a second phase III trial ...

Low-fat diets are problematic, says world-renowned internist and regenerative physician Michael Aziz, MD, author of the ...

Recent research has revealed innovative targets and therapeutic options. Liraglutide, a GLP-1 receptor agonist, has been shown to effectively lower glucagon levels and promote weight loss.